Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core.Borst, A.J., Weidle, C.E., Gray, M.D., Frenz, B., Snijder, J., Joyce, M.G., Georgiev, I.S., Stewart-Jones, G.B., Kwong, P.D., McGuire, A.T., DiMaio, F., Stamatatos, L., Pancera, M., Veesler, D.
(2018) Elife 7: --
- PubMed: 30403372
- DOI: 10.7554/eLife.37688
- Primary Citation of Related Structures:
- PubMed Abstract:
VRC01 broadly neutralizing antibodies (bnAbs) target the CD4-binding site (CD4 <sub>BS </sub>) of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein (Env). Unlike mature antibodies, corresponding VRC01 germline precursors poorly bind to ...
VRC01 broadly neutralizing antibodies (bnAbs) target the CD4-binding site (CD4 BS ) of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein (Env). Unlike mature antibodies, corresponding VRC01 germline precursors poorly bind to Env. Immunogen design has mostly relied on glycan removal from trimeric Env constructs and has had limited success in eliciting mature VRC01 bnAbs. To better understand elicitation of such bnAbs, we characterized the inferred germline precursor of VRC01 in complex with a modified trimeric 426c Env by cryo-electron microscopy and a 426c gp120 core by X-ray crystallography, biolayer interferometry, immunoprecipitation, and glycoproteomics. Our results show VRC01 germline antibodies interacted with a wild-type 426c core lacking variable loops 1-3 in the presence and absence of a glycan at position Asn276, with the latter form binding with higher affinity than the former. Interactions in the presence of an Asn276 oligosaccharide could be enhanced upon carbohydrate shortening, which should be considered for immunogen design.
Department of Biochemistry, University of Washington, Seattle, United States.,Department of Global Health, University of Washington, Seattle, United States.,Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States.,Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States.